For decades, women’s health was treated as a collection of specialty concerns rather than an essential part of the global health economy and comprehensive care. Fertility sat in one corner, menopause in another, while cardiovascular disease, autoimmune conditions, endometriosis and maternal health competed separately for research attention, investment and clinical urgency.

Women never experience their health that way. Their lives do not fit neatly into funding categories, medical specialties or isolated episodes of care. Health is a continuum that shifts over time, and the market is finally beginning to recognize its size, scientific potential, and human importance.

A new W Group study, “The Road to the Era of Scale,” provides compelling evidence of that shift. Based on the organization’s tracking of more than 500 funding stories and approximately 164 disclosed equity rounds across 15 categories and more than 30 countries, the report found that women’s health companies raised a record $1.55 billion in disclosed equity in 2025, a 41% increase from 2024.

A Market Is Forming, Not Merely Making Headlines

Investment totals can be deceptive. One enormous financing round can make an entire sector appear stronger, deeper, and more expansive than it is in reality. The significance of the W Group findings is that the capital did not simply increase. It spread over the continuum of women’s health.

Eighty-five women’s health companies raised equity in 2025, the highest annual number in the report’s data. Ten rounds reached at least $50 million, twice as many as in 2024, and the average disclosed round grew 29%, from approximately $13.9 million to $18 million.

Capital also became less concentrated among a few celebrated companies. The three largest rounds represented 39% of disclosed funding in 2024, compared with 32% in 2025. Funding received by companies outside the top three grew by 56%, a potential signal that investors are beginning to support a broader range of clinical needs, technologies and business models.

This is what the development of an investment ecosystem looks like. Capital begins to flow beyond the familiar names and into diagnostics, therapeutics, clinical infrastructure and care models that address different stages of a woman’s life.

Oncology received the largest share of investment, with the report estimating more than $600 million across at least 12 rounds. Fertility and assisted reproductive technology attracted more than $230 million, while maternal health drew approximately $160 million. Menopause, sexual and reproductive health, hormone diagnostics and pelvic health also received new support.

Endometriosis offers a particularly important example. Long dismissed, misunderstood and frequently diagnosed only after years of pain, the condition attracted more than $56 million across five rounds in 2025. The investments spanned therapeutics, diagnostics, and imaging, suggesting that the market is beginning to view endometriosis as a complex clinical challenge requiring multiple forms of innovation.

The same shift can be seen in metabolic health. SheMed’s $50 million Series A helped establish women-specific GLP-1 care as an investable category, reflecting the growing recognition that medicines, monitoring and health interventions must account for biological differences rather than treating the male body as the universal clinical norm.

The Women’s Health Innovation Map Is Becoming Global

The United States remains the dominant destination for women’s health capital, but the sector is no longer exclusively an American story. The US ecosystem also benefits from Organon, one of the few global pharmaceutical companies built around women’s health, whose portfolio, partnerships and commercial reach can help promising science cross the difficult divide between startup innovation and patient access.

Beyond the United States, the report found a broader geographic footprint in 2025, with companies and investors across Europe, Israel, India, Canada and the Middle East contributing to the market’s development.

The UK was the most active non-US ecosystem by company count in the W Group data. British companies were represented across metabolic health, endometriosis, hormone diagnostics, menstrual health, maternal care and other categories.

That entrepreneurial activity is now being matched by policy attention. England published a renewed 10-year Women’s Health Strategy in April 2026, aligned with the country’s broader health plan and centered on giving women greater voice, choice and power in decisions about their care. The government has also outlined efforts to streamline gynecologic care, improve access for conditions such as endometriosis and fibroids and confront inadequate approaches to women’s pain.

This matters because innovation cannot succeed through capital alone. A company may develop a better diagnostic or care platform. Still, its impact will remain limited unless clinicians trust it, health systems can adopt it, reimbursement supports it and patients can reach it. That is the difference between invention and innovation.

France is building another part of that infrastructure. The Île-de-France region has created FemTech Île-de-France, an investment fund targeting €50 million for women’s health innovation, supported by the scientific expertise of Université Paris Cité. Regional plans also include a specialized incubator effort and an interdisciplinary institute that connects research, clinical education, and innovation.

The French initiative is notable because it does not treat funding as an isolated intervention. It attempts to link capital with scientific expertise, company development and a regional health innovation strategy. That combination can help promising startups move beyond an initial idea and toward evidence, regulatory progress and clinical adoption.

France’s women’s health momentum is also reflected in Lyon-based Ziwig Biotech, whose Endotest uses salivary RNA analysis and artificial intelligence to provide a noninvasive diagnostic test for endometriosis, demonstrating how French biotechnology can turn a condition long marked by diagnostic delay into a precision-medicine opportunity.

Israel contributes another important dimension. Its health innovation culture is built upon deep scientific expertise, sophisticated health data, globally connected medical centers and an instinct for solving difficult clinical problems. In 2025, Israel presented a delegation of women’s health innovators at Expo 2025 Osaka, bringing companies and health leaders together with counterparts from Japan, the United States and Mexico.

Israel’s strength in technology, however, coexists with a persistent capital and leadership gap for women. An Israel Innovation Authority report found that women remain approximately one-third of the country’s high-tech workforce, while holding only 17% of senior management positions and 10% of startup CEO roles. The number of women working in research and development has risen sharply, but their representation in entrepreneurship, leadership and investment remains disproportionately low.

That disparity should concern anyone interested in women’s health innovation. When women are missing from the rooms where companies are founded, clinical priorities are established and capital is allocated, unmet needs are more likely to remain unseen.

The opportunity in Israel has two paths to consider. The country can export women’s health technologies to global markets while also ensuring that more women participate as founders, scientific leaders, investors and decision-makers shaping those innovations.

The Most Dangerous Gap Sits in the Middle

The report’s most urgent finding is not the record amount invested. It is the continuing Series A bottleneck.

Approximately 35-40 women’s health companies raised seed or pre-seed capital in each of the two years studied. Only about 20 to 25 reached Series A, and many companies that appeared at the seed stage in 2024 did not return with a Series A round in 2025.

Seed funding can demonstrate that a concept is interesting. Series A funding is often the stage at which a company must demonstrate that the concept can become clinically credible, commercially sustainable, and capable of operating within a complex health system.

This stage requires companies to generate evidence, recruit specialized talent, navigate regulation, protect sensitive patient information and establish a credible path to payment. It is also where founders discover that a technically elegant solution may not fit naturally into clinical workflows or address the daily realities faced by patients and health professionals.

The loss of promising companies at this stage is not only a financial concern. A stalled financing round can mean that an earlier diagnostic never reaches a physician, a new treatment never enters a clinical trial or a more humane care model never reaches the people who need it.

Specialist funds can help bridge that gap, and the report identified at least 11 new investment vehicles launched in 2025 with a women’s health mandate. Pharmaceutical companies and major generalist venture firms are also beginning to participate, an important sign that the sector is moving beyond support from a small circle of committed specialists.

The transition remains incomplete. Women’s health will not achieve sustained growth until generalist investors consider it a standard component of health investing rather than a special theme to be visited only occasionally.

Capital Still Follows Visibility More Than Burden

The funding pattern also reveals an uncomfortable truth. Conditions receiving the most investment are not always those creating the greatest health burden.

The report estimates that women-specific cardiovascular innovation received only about $2 million in dedicated equity during 2025. Dedicated investment addressing the women-specific dimensions of autoimmune disease was effectively absent, even though women account for the great majority of people living with autoimmune conditions. Mental health and pelvic health also remained dramatically underfunded in relation to their effects on people’s lives.

This does not diminish the importance of investment in fertility, oncology, menopause or maternal health. It does show that markets often follow categories that are easier to describe, sell or recognize before addressing conditions that are scientifically complex, poorly diagnosed or fragmented across medical specialties.

Cardiovascular disease in women is not a niche concern. Autoimmune disease is not a specialty-market curiosity. These are major health challenges that demand gender-specific research, earlier diagnosis, appropriate clinical evidence and investors prepared to build a long-term thesis.

Five years ago, menopause appeared similarly overlooked. Greater visibility, advocacy and scientific attention helped change investor understanding. Cardiovascular, autoimmune, and mental health innovation now requires a comparable shift.

Scale Must Mean Better Health Access, Not Only Larger Rounds

Investment is essential, but capital is not the same as care. A successful financing announcement does not reduce the years a woman may wait for an endometriosis diagnosis, reduce the risk of maternal complications or ensure that a new technology reaches people regardless of income or geography.

The true value of capital lies in what it enables people to create. It can help researchers produce evidence, enable founders to recruit skilled R&D teams and give companies time to earn the confidence of regulators, health professionals, payers and patients.

Technology should simplify care rather than introduce another point of friction. Data should help clinicians understand women more fully rather than reproduce historical bias. Artificial intelligence, or its application, should enhance human judgment, not serve as an excuse for health professionals to distance themselves from the people they serve.

The women’s health sector no longer needs to prove that unmet need exists. The record of delayed diagnoses, inadequate research, and dismissed symptoms has been established many times over.

It also no longer needs to prove that successful companies can be created. The expansion of investment across more categories, countries and later-stage rounds shows that women’s health can produce significant scientific advances and scalable enterprises.

The question now is whether investors, policymakers and health systems will support those companies through the winding journey from possibility to practice. That will require patient capital, stronger evidence, workable reimbursement pathways, and a willingness to design care around women’s lives rather than forcing women to navigate systems not designed with them in mind.

The W Group Era of Scale analysis should not be measured only by how much capital enters women’s health. It should be measured by whether that investment leads to earlier diagnoses, better treatments, broader access and less suffering. The true measure of scale will not be dollars invested, but lives improved.